


LENZ & STAEHELIN ADVISES BAIN CAPITAL PRIVATE EQUITY AND CINVEN

Posted on 9 February 2021



Category: [Deal & transactions](#)

Tags: [Alex Wille](#), [Anja Affolter Marino](#), [Astrid Waser](#), [Beat Kühni](#), [David Hitz](#), [Eric Meier](#), [Ex-Featured](#), [Kevin MacCabe](#), [Leo Rusterholz](#), [Lisa Moser](#), [Lukas Aebi](#), [Marcel Tranchet](#), [Pascal Hinny](#), [Roland Fischer](#), [Tino Gaberthüel](#), [Tobias Weber](#), [Xavier Grivel](#)



On February 8, 2021, **Bain Capital Private Equity** and **Cinven** have entered into definitive agreements to acquire **Lonza Specialty Ingredients**, a division of Lonza AG, for a total enterprise value of CHF 4.2 billion. The transaction is expected to close in the second half of 2021, subject to customary closing conditions.

The team

Lenz & Staehelin [advises Bain Capital Private Equity and Cinven on this transaction.](#)

The team includes partners Tino Gaberthüel (Corporate / M&A - pictured), Beat Kühni (Real Estate), Marcel Tranchet (Finance), Astrid Waser (Competition) and Pascal Hinny (Tax) as well as Eric Meier, Alex Wille, Xavier Grivel and Lisa Moser (all Corporate and M&A), Tobias Weber (Real Estate), Roland Fischer, Kevin MacCabe (both Finance), Anja Affolter Marino (Employment/Pension), Leo Rusterholz (IT, Data

Protection, Transitional Services), Lukas Aebi (Tax) and David Hitz (IP).

Headquartered in Basel, LSI has approximately 2,800 employees, 11 R&D centres and 17 manufacturing sites across the world. LSI is a global provider of specialty chemicals for microbial control solutions, used to eliminate or control harmful and unwanted micro-organisms. The business also produces a range of other specialty chemicals, centred around its unique production facility in Switzerland. The business serves approx. 5,300 customers across a wide range of end-markets.